SlideShare a Scribd company logo
Propofol ppt nandini
 Propofol is famously called as “Milk of
Amnesia”.
 Most common intravenous agent used for
induction and maintenance of
Anaesthesia.
 Preferred drug in Day care surgeries.
 Also used for sedation in intubated and
mechanically ventilated patients in ICU.
 The best choice in TIVA.
 Diprivan(1%)- 10% soyabean oil, 2.25%
glycerol, 1.2% egg phosphatide ,
0.005%disodium edenate.
 Ampofol(low lipid emulsion)- 5%soyabean
oil, 0.6% egg lecithin
 Diprifusor TCI devices
 Propofol lipura
 Fospropofol(Lusedra/Aquavan)
 Milky white coloured , sterile , non pyrogenic
oil in water emulsion
 Highly lipid soluble
 Slightly water soluble
 Molecular weight -178.271 D
 Octanol water partition coefficient-6761:1 at
pH- 6 to8.5
 Isotonic, pH-7-8.5
 2,6- diisopropylphenol(C12H18O)
 Weak acid, unionized, Pka-11
 Protein binding-95-98%
Propofol ppt nandini
 Main Site of action - GABAa-BZD: Chloride
receptor complex in CNS - Binding of
propofol to GABAa receptor causes
prolongation of action of GABA and
increased duration of opening of chloride
channel resulting in hyperpolarization of
postsynaptic cell membrane and functional
inhibition of post synaptic neurons.
 Acts on hippocampus and prefrontal
cortex .
 Principal action responsible for sedation
and hypnosis.
 Widespread inhibition of NMDA(N-methyl-D-
aspartate) receptor through sodium channel
gating.
 Acts on GABA a and glycine receptors on
dorsal horn of spinal cord and inhibits the
excitatory action.
 Increases Dopamine concentration in nucleus
accumbens which is responsible for sense of
well being, drug abuse potential and pleasure
seeking behaviour.
 Decreases serotonin levels in area postrema –
anti emetic effect.
 Absorption- Intravenous
 Volume of distribution-3.5-4-5 L/kg
 Distribution- explained by three compartment linear model
 Rapidly equilibrates between plasma and brain accounting
for rapid onset of anaesthesia(one brain arm circulation
time)
 Onset-<40 seconds, peak effect -90-100 seconds, initial
redistribution half life-2-8minutes.
 Phase 1/very rapid distribution(half life- 1-8min)- rapidly
distributed to highly perfused organs like heart , lungs,
kidneys and liver.
 Phase 2/slow distribution(half life-30 -60 min)- rapidly
distributed from highly perfused tissues to muscle and fat.
 Phase 3/terminal elimination(half life-4 to24 hrs)-slowly
released from deep compartment with limited perfusion (fat)
to plasma and is metabolized.
 Elimination half time- 0.5 hrs -1.5 hrs
 Context sensitive half time- <40 min-8 hrs
 Short effect-site equilibration time
 Clearance rate-30-60ml/kg/min
 Metabolism- propofol is extensively metabolized by liver .It
undergoes conjugation by UDP-glucoronosyl transferase to form
inactive, water soluble sulfate and glucoronic acid metabolites which
are excreted by the kidneys.
 Propofol may also undergo ring hydroxylation by cytochrome-P450 to
form 4- hydroxypropofol which is then glucoronidated or sulfated.
 Extra-hepatic metabolism- Lungs-30% uptake(propofol converted to
2,6-diisopropyl-1,4-quinol) and kidneys -30%uptake.
 Less than 1%propofol is excreted unchanged in urine and only 2%in
faeces.
 No dosage adjustments are needed for patients with renal or hepatic
failure
 Geriatrics
age-related decrease in volume of distribution
Decresed rate of plasma clearance
cardiorespiratory effects including hypotension, apnea, airway
obstruction, and/or oxygen desaturation
 Blood levels of propofol during surgery
required for unconsciousness- 2-5 ug/ml.
 Patient becomes awake at plasma level less
than 1.5 ug/ml.
 ED90 for anaesthesia is 3.2ug/ml when
used with 67% of nitrous oxide.
 Larger doses required in children- higher
clearance rate(25%) and larger central
compartment volume(50%).
 CNS- decrease in cerebral metabolic oxygen
consumption, cerebral blood flow, ICP and cerebral
perfusion pressure.
 Cerebral autoregulation and reactivity to increased
PaCO2 is maintained.
 CVS- decreases SVR by 30%, decreases SBP by 25-40%
along with decrease in COP.
 Propofol blocks/resets baroreceptors, so there is little
(no) compensatory tachycardia due to decrease in
mean BP.
 A central cholinergic response may be responsible for
bradycardia.
 If ventilation is assisted or controlled(CPAP), there is
increase in the incidence and degree of depression on
COP.
 RS- dose dependent respiratory depression(first
reduction in tidal volume associated with tachypnoea
followed by apnoea).
 Apnoeaoccure in 25-30% of patients depending on the
dose and use of concomitant drugs like opoids, BZP .
 Decreased sensitvity of respiratory centre to increase
in CO2 and hypoxia via carotid body chemoreceptors.
 Laryngeal and cough reflexes are depressed.
 Propofol has a bronchodilator effect through direct
action on muscaranic action and attenuating vagal
response.
 Attenuates the magnitude of hypoxic pulmonary
vasoconstriction.
 Liver- blood flow is decreased. Prolonged infusions
have been associated with hepatocellular injury
accompanied by lactic acidosis, bradydysarrythmias
and rhabdomolysis.
 Kidney- vasoconstriction of splanchnic and renal
blood vessels which causes decrease in RBF and GFR.
 Prolonged infusions results in green urine due to
phenols in urine and due to increased uric acid
crystals in urine.
 Eyes- decrease in IOP by 30-40%, helps in blunting
increase in IOP due to succinylcholine or laryngoscopy.
 Pregnant uterus- crosses placenta (equilibrium
between mother and foetus is 2-3 min) and causes
neonatal depression.
 induction and maintenance of anesthesia
 Monitored anaesthesia care(MAC) sedation
 Combined sedation and regional
anaesthesia
 Short surgical procedure, ICU
sedation ,conscious sedation.
 Anti-emetic- 10-20 mg IV ,can be
repeated every 5-10 min or start infusion
of 10 ug/kg/min.
 Anti-pruritic- 10 mg IV is effective in the
treatment of pruritis associated with
neuraxial opoids and cholelithiasis.
 Attenuation of bronchospasm- Hence,
useful in asthamatics.
 Antioxidant- beneficial in acute lung
injury.
 Healthy Adults Less Than 55 Years of Age: 40 mg
every 10 seconds until induction onset (2-2.5
mg/kg).
 Elderly, Debilitated, or ASA III/IV Patients: 20 mg
every 10 seconds until induction onset (1-1.5
mg/kg).
 Cardiac Anesthesia: 20 mg every 10 seconds until
induction onset (0.5-1.5 mg/kg).
 Neurosurgical Patients: 20 mg every 10 seconds
until induction onset (1-2 mg/kg).
 Pediatric Patients - healthy, from 3-16 years of
age: 2.5-3.5 mg/kg administered over 20-30
seconds.
 Healthy Adults Less Than 55 Years of Age: 100-
200 μg/kg/min (6-12 mg/kg/h).
 Elderly, Debilitated, ASA III/IV Patients: 50-100
μg/kg/min (3-6 mg/kg/h).
 Pediatric Patients - healthy, from 2 months to 16
years of age: 125-300 μg/kg/min (7.5-18
mg/kg/h)
 Cardiac Anesthesia, Most Patients Require:
Primary propofol injectable emulsion with
secondary opioid: 100-150 μg/kg/min. Low-dose
propofol injectable emulsion with primary opioid:
50-100 μg/kg/min.
 Neurosurgical Patients: 100-200 μg/kg/min (6-
12 mg/kg/h).
 Initiation of MAC sedation- Healthy adults <55
yrs of age: most patients require an infusion of
100-150 ug/kg/min(6-9mg/kg/hr) for 3-5min or
a slow injection of 0.5 mg/kg over 3-5 min
followed immediately by a maintenance infusion.
 Elderly , debiliated, neurosurgical or ASA- III/IV
patients- require doses similar to healthy adults
but rapid boluses are to be avoided.
 Maintenance of MAC sedation- Healthy adults
<55 yrs of age: 25-75 ug/kg/min(1.5-4.5
mg/kg/hr)or incremental doses of 10 mg or 20
mg.
 Elderly , debiliated, neurosurgical or ASA- III/IV
patients- require 80% of the usual adult dose, but
rapid boluses are to be avoided.
 2 % aqueous solution of propofol is used in
ICU for initiation and maintenance of
sedation in intubated and mechanically
ventilated patients
 Initiation: 5 ug/kg/min(0.3 mg/kg/hr) for
at least 5 min with subsequent increments
of 5-10 ug/kg/min(0.3-0.6 mg/kg/hr)
over 5-10 min.
 Maintenance: 5-50 ug/kg/min(0.3-3
mg/kg/hr) or higher my be required.
 Airway
 Copious secretions
 Laryngospasm
 Respiratory
 Apnea, respiratory depression
 Hiccough
 Bronchospasm
 Cardiovascular
 Hypotension
 Dysrhythmias, bradycardia or tachycardia
 Central Nervous System
 Headache
 Dizziness, euphoria, confusion
 Clonic/myoclonic movements
 Seizures, disinhibition
 Other
 Pain or burning at the injection site is common
especially when the IV is in a small peripheral
vein
 Green urine
 Transient local pain: larger veins; prior
injection of IV lidocaine (1 ml of a 1% solution),
not exceeding 20 mg lidocaine/200mg
propofol.
 Post operative unconsciousness.
 rare reports of pulmonary edema.
 unexplained postoperative pancreatitis
 Pediatric patients
 no vagolytic activity
 Reports of bradycardia, asystole, and rarely, cardiac
arrest have been associated with propofol
 particularly when fentanyl is given
 anticholinergic agents
•Propofol is known to have
effects like amorous
behaviour , intense dreaming
and hallucinations.
•The famous legendary
singer Michael Jackson died
due to acute propofol and
benzodiazepine intoxication.
 It has been described in pediatric and adult patients
receiving prolonged infusions of propofol at
>75ug/kg/min(>5 mg/kg/hr) for>24-48 hrs.
 It is a rare but lethal complication .
 Basic pathology-mitochondrial toxicity(impaired oxidation
of long chain fatty acids affecting electron transport chain),
impaired tissue oxygenation and carbohydrate deficiency.
 Presentation- acute refractory bradycardia leaading to
asystole in presence of one or more of the following:
metabolic acidosis(base deficit>10 mmol/l),
hyperlipedemia, rhabdomyolysis, enlarged or fatty liver,
cardiomyopathy with acute cardiac failure and hyperkalemia.
 Treatment- prompt recognition of symptoms and
discontinuation of propofol infusion. ECMO(extra corporeal
membrane oxygenation) has been described in treatment of
some patients.
 Absolute contraindications:
1. Known hypersensitvity to propofol or any of its
components.
2. Allergies to egg, egg products, soyabeans or soy
products.
3. Disorders of fat metabolism.
 Relative contraindications:
1. Untreated hypertensive, hypovolemia and compromised
left ventricular function.
2. Paediatric patients <3 yrs.
3. Pregnant or lactating mother.
4. Known case of epilepsy.
5. Patients undergoing neurosurgery such as pallidotomy
as it temporary abolishes tremors in patients of
parkinsonism.
 dose requirements reduced:
 Premedication with narcotics (e.g., morphine,
meperidine, and fentanyl, etc.)
 In pediatric patients, administration of fentanyl
concomitantly with propofol may result in
serious bradycardia
 combinations of opioids and sedatives (e.g.,
benzodiazepines, barbiturates, chloral hydrate,
droperidol, etc.)
 more pronounced decreases in systolic,
diastolic, and mean arterial pressures and
cardiac output
 reduced in the presence nitrous oxide
 inhalational agents (e.g., isoflurane, enflurane, and
halothane) has not been extensively evaluated
 does not cause a clinically significant change in
onset, intensity or duration of action of the
commonly used neuromuscular blocking agents
(e.g., succinylcholine and nondepolarizing muscle
relaxants).
 Coadministration of 10 microg kg(-1)midazolam
decreases the dose and time required to achieve
hypnosis with propofol induction without delaying
emergence from anesthesia.
 Additional administration of flumazenil further
shortens the time to emerge from midazolam-
propofol anesthesia
 CONCLUSIONS:
 The plasma levels of fentanyl affect the concentrations of
propofol required for patients to regain consciousness.
 The BIS values for wakefulness are unaltered at the
different combinations of propofol and fentanyl
concentrations. Thus, the BIS appears to be a useful and
consistent indicator for level of consciousness during
emergence from propofol/fentanyl intravenous
anesthesia
 Pharmacology and physiology in
Anaesthetic practice- fourth edition-
Stoelting.
 Miller’s Anaesthesia- seventh edition.
 Lee’s synopsis of Anaesthesia.
 Journal of Clinical Anesthesia
Volume 13 • Number 4 • June 2001
Copyright © 2001 Elsevier
Propofol ppt nandini

More Related Content

PDF
PPTX
Thiopentone and propofol
PPT
Intravenous induction agents
PPTX
Nursing care of unconscious Patient
PPTX
Neuromuscular physiology
PPTX
Propofol - pharmacology, MOA USES, SIDE EFFECTS
PPTX
Lower limb blocks
PPTX
Pre-oxygenation
Thiopentone and propofol
Intravenous induction agents
Nursing care of unconscious Patient
Neuromuscular physiology
Propofol - pharmacology, MOA USES, SIDE EFFECTS
Lower limb blocks
Pre-oxygenation

What's hot (20)

PPTX
Caudal anesthesia
PPTX
Spinal anesthesia
PPTX
epidural anesthesia
PPTX
Supraglottic airway device
PPTX
Dexmedetomidine
PPT
Spinal anesthesia
PPTX
Glycopyrrolate
PDF
Induction Agents - Propofol, Sodium Thiopental, Ketamine,
PPTX
supraglottic airway devices
PPT
SPINAL ANAESTHESIA
PPTX
PPTX
Intravenous Induction agents
PPTX
Epidural anesthesia
PPTX
Dexmedetomidine
PPT
Inhalational Anesthetic Agents
PPTX
Total Intravenous Anaesthesia
PPTX
Atracurium Vecuronium Pancuronium
PPTX
Spinal & epidural needle
PPTX
Peripheral nerve blocks
Caudal anesthesia
Spinal anesthesia
epidural anesthesia
Supraglottic airway device
Dexmedetomidine
Spinal anesthesia
Glycopyrrolate
Induction Agents - Propofol, Sodium Thiopental, Ketamine,
supraglottic airway devices
SPINAL ANAESTHESIA
Intravenous Induction agents
Epidural anesthesia
Dexmedetomidine
Inhalational Anesthetic Agents
Total Intravenous Anaesthesia
Atracurium Vecuronium Pancuronium
Spinal & epidural needle
Peripheral nerve blocks
Ad

Similar to Propofol ppt nandini (20)

PPTX
INTRA VENOUS INDUCING AGENTS
PPTX
Intravenous induction agents
PPTX
Intravenous (IV) Anaesthetic Agents .pptx
PPTX
PROPOFOL an inducing agent presentation.
PPT
pediatric Anesthesia presentation copy.ppt
PPTX
Antiarrhythmics
PPT
Propofol & Etomidate - pharmacology and its use
PPTX
Intravenous inductional agents ( anesthesiology & critical care)
PPT
anesthetics.pptanesthetics.pptanesthetics.ppt
PPT
GA.ppt GENERAL ANESTHETICSGENERAL ANESTHETICS
PPTX
Vasopressors
PPTX
paediatric anaesthesia.pptx 2.pptx
PPTX
Neuromuscle Relaxants and Reversal Agents.pptx
PPTX
OPIOIDS ii.pptx
PDF
Ped medhandbook
PDF
Ped medhandbook
PPT
Diabetic ketoacidosis ppt
PPTX
Anti arrhythmic drugs cardiovascular.pptx
PPT
anaesthesia for laparoscopic surgery.ppt
INTRA VENOUS INDUCING AGENTS
Intravenous induction agents
Intravenous (IV) Anaesthetic Agents .pptx
PROPOFOL an inducing agent presentation.
pediatric Anesthesia presentation copy.ppt
Antiarrhythmics
Propofol & Etomidate - pharmacology and its use
Intravenous inductional agents ( anesthesiology & critical care)
anesthetics.pptanesthetics.pptanesthetics.ppt
GA.ppt GENERAL ANESTHETICSGENERAL ANESTHETICS
Vasopressors
paediatric anaesthesia.pptx 2.pptx
Neuromuscle Relaxants and Reversal Agents.pptx
OPIOIDS ii.pptx
Ped medhandbook
Ped medhandbook
Diabetic ketoacidosis ppt
Anti arrhythmic drugs cardiovascular.pptx
anaesthesia for laparoscopic surgery.ppt
Ad

More from Dr Nandini Deshpande (8)

PPTX
Perioperative Arrythmias and management
PPTX
Copd and anaesthetic considerations
PPTX
Anaesthesia for non obstetric surgery in pregnancy
PPTX
Anaesthesia for foetal surgeries
PPTX
Dvt prophylaxis , treatment and anaesthetic considerations
PPTX
Geriatric anaesthesia
PPTX
Final anaphylactic reactions and anaphylactic shock
PPTX
Anaesthetic management of a patient with perioperative asthma
Perioperative Arrythmias and management
Copd and anaesthetic considerations
Anaesthesia for non obstetric surgery in pregnancy
Anaesthesia for foetal surgeries
Dvt prophylaxis , treatment and anaesthetic considerations
Geriatric anaesthesia
Final anaphylactic reactions and anaphylactic shock
Anaesthetic management of a patient with perioperative asthma

Recently uploaded (20)

PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
Respiratory drugs, drugs acting on the respi system
PPTX
Uterus anatomy embryology, and clinical aspects
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPT
OPIOID ANALGESICS AND THEIR IMPLICATIONS
PPTX
Fundamentals of human energy transfer .pptx
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPTX
Neurotransmitter, Types of neurotransmitters,Neurotransmitter function, Neur...
PPTX
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx
PPTX
Neuropathic pain.ppt treatment managment
PDF
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
PPT
Obstructive sleep apnea in orthodontics treatment
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
PPTX
ACID BASE management, base deficit correction
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
History and examination of abdomen, & pelvis .pptx
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PPTX
SKIN Anatomy and physiology and associated diseases
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Respiratory drugs, drugs acting on the respi system
Uterus anatomy embryology, and clinical aspects
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
OPIOID ANALGESICS AND THEIR IMPLICATIONS
Fundamentals of human energy transfer .pptx
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
Neurotransmitter, Types of neurotransmitters,Neurotransmitter function, Neur...
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx
Neuropathic pain.ppt treatment managment
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
Obstructive sleep apnea in orthodontics treatment
CT Anatomy for Radiotherapy.pdf eryuioooop
ACID BASE management, base deficit correction
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
History and examination of abdomen, & pelvis .pptx
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
SKIN Anatomy and physiology and associated diseases

Propofol ppt nandini

  • 2.  Propofol is famously called as “Milk of Amnesia”.  Most common intravenous agent used for induction and maintenance of Anaesthesia.  Preferred drug in Day care surgeries.  Also used for sedation in intubated and mechanically ventilated patients in ICU.  The best choice in TIVA.
  • 3.  Diprivan(1%)- 10% soyabean oil, 2.25% glycerol, 1.2% egg phosphatide , 0.005%disodium edenate.  Ampofol(low lipid emulsion)- 5%soyabean oil, 0.6% egg lecithin  Diprifusor TCI devices  Propofol lipura  Fospropofol(Lusedra/Aquavan)
  • 4.  Milky white coloured , sterile , non pyrogenic oil in water emulsion  Highly lipid soluble  Slightly water soluble  Molecular weight -178.271 D  Octanol water partition coefficient-6761:1 at pH- 6 to8.5  Isotonic, pH-7-8.5  2,6- diisopropylphenol(C12H18O)  Weak acid, unionized, Pka-11  Protein binding-95-98%
  • 6.  Main Site of action - GABAa-BZD: Chloride receptor complex in CNS - Binding of propofol to GABAa receptor causes prolongation of action of GABA and increased duration of opening of chloride channel resulting in hyperpolarization of postsynaptic cell membrane and functional inhibition of post synaptic neurons.  Acts on hippocampus and prefrontal cortex .  Principal action responsible for sedation and hypnosis.
  • 7.  Widespread inhibition of NMDA(N-methyl-D- aspartate) receptor through sodium channel gating.  Acts on GABA a and glycine receptors on dorsal horn of spinal cord and inhibits the excitatory action.  Increases Dopamine concentration in nucleus accumbens which is responsible for sense of well being, drug abuse potential and pleasure seeking behaviour.  Decreases serotonin levels in area postrema – anti emetic effect.
  • 8.  Absorption- Intravenous  Volume of distribution-3.5-4-5 L/kg  Distribution- explained by three compartment linear model  Rapidly equilibrates between plasma and brain accounting for rapid onset of anaesthesia(one brain arm circulation time)  Onset-<40 seconds, peak effect -90-100 seconds, initial redistribution half life-2-8minutes.  Phase 1/very rapid distribution(half life- 1-8min)- rapidly distributed to highly perfused organs like heart , lungs, kidneys and liver.  Phase 2/slow distribution(half life-30 -60 min)- rapidly distributed from highly perfused tissues to muscle and fat.  Phase 3/terminal elimination(half life-4 to24 hrs)-slowly released from deep compartment with limited perfusion (fat) to plasma and is metabolized.
  • 9.  Elimination half time- 0.5 hrs -1.5 hrs  Context sensitive half time- <40 min-8 hrs  Short effect-site equilibration time  Clearance rate-30-60ml/kg/min  Metabolism- propofol is extensively metabolized by liver .It undergoes conjugation by UDP-glucoronosyl transferase to form inactive, water soluble sulfate and glucoronic acid metabolites which are excreted by the kidneys.  Propofol may also undergo ring hydroxylation by cytochrome-P450 to form 4- hydroxypropofol which is then glucoronidated or sulfated.  Extra-hepatic metabolism- Lungs-30% uptake(propofol converted to 2,6-diisopropyl-1,4-quinol) and kidneys -30%uptake.  Less than 1%propofol is excreted unchanged in urine and only 2%in faeces.  No dosage adjustments are needed for patients with renal or hepatic failure  Geriatrics age-related decrease in volume of distribution Decresed rate of plasma clearance cardiorespiratory effects including hypotension, apnea, airway obstruction, and/or oxygen desaturation
  • 10.  Blood levels of propofol during surgery required for unconsciousness- 2-5 ug/ml.  Patient becomes awake at plasma level less than 1.5 ug/ml.  ED90 for anaesthesia is 3.2ug/ml when used with 67% of nitrous oxide.  Larger doses required in children- higher clearance rate(25%) and larger central compartment volume(50%).
  • 11.  CNS- decrease in cerebral metabolic oxygen consumption, cerebral blood flow, ICP and cerebral perfusion pressure.  Cerebral autoregulation and reactivity to increased PaCO2 is maintained.  CVS- decreases SVR by 30%, decreases SBP by 25-40% along with decrease in COP.  Propofol blocks/resets baroreceptors, so there is little (no) compensatory tachycardia due to decrease in mean BP.  A central cholinergic response may be responsible for bradycardia.  If ventilation is assisted or controlled(CPAP), there is increase in the incidence and degree of depression on COP.
  • 12.  RS- dose dependent respiratory depression(first reduction in tidal volume associated with tachypnoea followed by apnoea).  Apnoeaoccure in 25-30% of patients depending on the dose and use of concomitant drugs like opoids, BZP .  Decreased sensitvity of respiratory centre to increase in CO2 and hypoxia via carotid body chemoreceptors.  Laryngeal and cough reflexes are depressed.  Propofol has a bronchodilator effect through direct action on muscaranic action and attenuating vagal response.  Attenuates the magnitude of hypoxic pulmonary vasoconstriction.
  • 13.  Liver- blood flow is decreased. Prolonged infusions have been associated with hepatocellular injury accompanied by lactic acidosis, bradydysarrythmias and rhabdomolysis.  Kidney- vasoconstriction of splanchnic and renal blood vessels which causes decrease in RBF and GFR.  Prolonged infusions results in green urine due to phenols in urine and due to increased uric acid crystals in urine.  Eyes- decrease in IOP by 30-40%, helps in blunting increase in IOP due to succinylcholine or laryngoscopy.  Pregnant uterus- crosses placenta (equilibrium between mother and foetus is 2-3 min) and causes neonatal depression.
  • 14.  induction and maintenance of anesthesia  Monitored anaesthesia care(MAC) sedation  Combined sedation and regional anaesthesia  Short surgical procedure, ICU sedation ,conscious sedation.
  • 15.  Anti-emetic- 10-20 mg IV ,can be repeated every 5-10 min or start infusion of 10 ug/kg/min.  Anti-pruritic- 10 mg IV is effective in the treatment of pruritis associated with neuraxial opoids and cholelithiasis.  Attenuation of bronchospasm- Hence, useful in asthamatics.  Antioxidant- beneficial in acute lung injury.
  • 16.  Healthy Adults Less Than 55 Years of Age: 40 mg every 10 seconds until induction onset (2-2.5 mg/kg).  Elderly, Debilitated, or ASA III/IV Patients: 20 mg every 10 seconds until induction onset (1-1.5 mg/kg).  Cardiac Anesthesia: 20 mg every 10 seconds until induction onset (0.5-1.5 mg/kg).  Neurosurgical Patients: 20 mg every 10 seconds until induction onset (1-2 mg/kg).  Pediatric Patients - healthy, from 3-16 years of age: 2.5-3.5 mg/kg administered over 20-30 seconds.
  • 17.  Healthy Adults Less Than 55 Years of Age: 100- 200 μg/kg/min (6-12 mg/kg/h).  Elderly, Debilitated, ASA III/IV Patients: 50-100 μg/kg/min (3-6 mg/kg/h).  Pediatric Patients - healthy, from 2 months to 16 years of age: 125-300 μg/kg/min (7.5-18 mg/kg/h)  Cardiac Anesthesia, Most Patients Require: Primary propofol injectable emulsion with secondary opioid: 100-150 μg/kg/min. Low-dose propofol injectable emulsion with primary opioid: 50-100 μg/kg/min.  Neurosurgical Patients: 100-200 μg/kg/min (6- 12 mg/kg/h).
  • 18.  Initiation of MAC sedation- Healthy adults <55 yrs of age: most patients require an infusion of 100-150 ug/kg/min(6-9mg/kg/hr) for 3-5min or a slow injection of 0.5 mg/kg over 3-5 min followed immediately by a maintenance infusion.  Elderly , debiliated, neurosurgical or ASA- III/IV patients- require doses similar to healthy adults but rapid boluses are to be avoided.  Maintenance of MAC sedation- Healthy adults <55 yrs of age: 25-75 ug/kg/min(1.5-4.5 mg/kg/hr)or incremental doses of 10 mg or 20 mg.  Elderly , debiliated, neurosurgical or ASA- III/IV patients- require 80% of the usual adult dose, but rapid boluses are to be avoided.
  • 19.  2 % aqueous solution of propofol is used in ICU for initiation and maintenance of sedation in intubated and mechanically ventilated patients  Initiation: 5 ug/kg/min(0.3 mg/kg/hr) for at least 5 min with subsequent increments of 5-10 ug/kg/min(0.3-0.6 mg/kg/hr) over 5-10 min.  Maintenance: 5-50 ug/kg/min(0.3-3 mg/kg/hr) or higher my be required.
  • 20.  Airway  Copious secretions  Laryngospasm  Respiratory  Apnea, respiratory depression  Hiccough  Bronchospasm  Cardiovascular  Hypotension  Dysrhythmias, bradycardia or tachycardia
  • 21.  Central Nervous System  Headache  Dizziness, euphoria, confusion  Clonic/myoclonic movements  Seizures, disinhibition  Other  Pain or burning at the injection site is common especially when the IV is in a small peripheral vein  Green urine
  • 22.  Transient local pain: larger veins; prior injection of IV lidocaine (1 ml of a 1% solution), not exceeding 20 mg lidocaine/200mg propofol.  Post operative unconsciousness.  rare reports of pulmonary edema.  unexplained postoperative pancreatitis  Pediatric patients  no vagolytic activity  Reports of bradycardia, asystole, and rarely, cardiac arrest have been associated with propofol  particularly when fentanyl is given  anticholinergic agents
  • 23. •Propofol is known to have effects like amorous behaviour , intense dreaming and hallucinations. •The famous legendary singer Michael Jackson died due to acute propofol and benzodiazepine intoxication.
  • 24.  It has been described in pediatric and adult patients receiving prolonged infusions of propofol at >75ug/kg/min(>5 mg/kg/hr) for>24-48 hrs.  It is a rare but lethal complication .  Basic pathology-mitochondrial toxicity(impaired oxidation of long chain fatty acids affecting electron transport chain), impaired tissue oxygenation and carbohydrate deficiency.  Presentation- acute refractory bradycardia leaading to asystole in presence of one or more of the following: metabolic acidosis(base deficit>10 mmol/l), hyperlipedemia, rhabdomyolysis, enlarged or fatty liver, cardiomyopathy with acute cardiac failure and hyperkalemia.  Treatment- prompt recognition of symptoms and discontinuation of propofol infusion. ECMO(extra corporeal membrane oxygenation) has been described in treatment of some patients.
  • 25.  Absolute contraindications: 1. Known hypersensitvity to propofol or any of its components. 2. Allergies to egg, egg products, soyabeans or soy products. 3. Disorders of fat metabolism.  Relative contraindications: 1. Untreated hypertensive, hypovolemia and compromised left ventricular function. 2. Paediatric patients <3 yrs. 3. Pregnant or lactating mother. 4. Known case of epilepsy. 5. Patients undergoing neurosurgery such as pallidotomy as it temporary abolishes tremors in patients of parkinsonism.
  • 26.  dose requirements reduced:  Premedication with narcotics (e.g., morphine, meperidine, and fentanyl, etc.)  In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia  combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.)  more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output
  • 27.  reduced in the presence nitrous oxide  inhalational agents (e.g., isoflurane, enflurane, and halothane) has not been extensively evaluated  does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants).  Coadministration of 10 microg kg(-1)midazolam decreases the dose and time required to achieve hypnosis with propofol induction without delaying emergence from anesthesia.  Additional administration of flumazenil further shortens the time to emerge from midazolam- propofol anesthesia
  • 28.  CONCLUSIONS:  The plasma levels of fentanyl affect the concentrations of propofol required for patients to regain consciousness.  The BIS values for wakefulness are unaltered at the different combinations of propofol and fentanyl concentrations. Thus, the BIS appears to be a useful and consistent indicator for level of consciousness during emergence from propofol/fentanyl intravenous anesthesia
  • 29.  Pharmacology and physiology in Anaesthetic practice- fourth edition- Stoelting.  Miller’s Anaesthesia- seventh edition.  Lee’s synopsis of Anaesthesia.  Journal of Clinical Anesthesia Volume 13 • Number 4 • June 2001 Copyright © 2001 Elsevier